Friday, October 7, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it completed enrollment and randomization of 121 patients in a Phase II trial of bavituximab in combination with docetaxel in previously treated, locally advanced or metastatic non-small-cell lung cancer (NSCLC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.